Cargando…
To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations
INTRODUCTION: Lung cancer is one of primary cancer type with high incidence and mortality, non-small cell lung cancer (NSCLC) is the most common type of lung cncer. For advanced lung cancer, traditional chemotherapy and targeted therapy become difficult to solve the dilemma of further progress. In r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423141/ https://www.ncbi.nlm.nih.gov/pubmed/37261523 http://dx.doi.org/10.1007/s00432-023-04919-4 |
_version_ | 1785089380965154816 |
---|---|
author | Cai, Ruoxue Zhu, Hongyu Liu, Ying Sha, Huanhuan Peng, Weiwei Yin, Rong Zhou, Guoren Fang, Ying |
author_facet | Cai, Ruoxue Zhu, Hongyu Liu, Ying Sha, Huanhuan Peng, Weiwei Yin, Rong Zhou, Guoren Fang, Ying |
author_sort | Cai, Ruoxue |
collection | PubMed |
description | INTRODUCTION: Lung cancer is one of primary cancer type with high incidence and mortality, non-small cell lung cancer (NSCLC) is the most common type of lung cncer. For advanced lung cancer, traditional chemotherapy and targeted therapy become difficult to solve the dilemma of further progress. In recent years, with the clinical application of immunotherapy, the therapeutic strategy of lung cancer has changed dramatically. At present, immunotherapy has shown conspicuous efficacy in NSCLC patients with high expression of programmed death-ligand 1 (PD-L1) and high tumor mutational burden (TMB). The discovery of driver mutations brings delightful hope for targeted cancer therapy. However, it remains controversial whether immunotherapy can be used in NSCLC patients with these specific driver mutations. METHOD: This article summarized the latest research progresses of immunotherapy in advanced NSCLC. We paid close attention to the relevance of various driver mutations and immunotherapy in NSCLC patients, and summarized the predictive effects of several driver mutations and immunotherapy. RESULTS: The mutations of KRAS, KRAS+TP53, EPHA (especially EPHA5), ZFHX3, ZFHX3+TP53, NOTCH, BRAF and LRP1B+FAT3 have potential to be used as biomarkers to predict the positive effectiveness of immunotherapy. ZFHX3, ZFHX3+TP53, STKII/LKB1+KEAP1+SMARCA4+PBRM1 mutations in LUAD patients get more positive effect in immunotherapy. While the mutations of EGFR, KEAP1, STKII/LKB1+KRAS, EML4-ALK, MET exon 14 skipping mutation, PBRM1, STKII/LKB1+KEAP1+SMARCA4+PBRM1, ERBB2, PIK3CA and RET often indicate poor benefit from immunotherapy. CONCLUSION: Many gene mutations have been shown to be associated with immunotherapy efficacy. Gene mutations should be combined with PD-L1, TMB, etc. to predict the effect of immunotherapy. |
format | Online Article Text |
id | pubmed-10423141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-104231412023-08-14 To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations Cai, Ruoxue Zhu, Hongyu Liu, Ying Sha, Huanhuan Peng, Weiwei Yin, Rong Zhou, Guoren Fang, Ying J Cancer Res Clin Oncol Review INTRODUCTION: Lung cancer is one of primary cancer type with high incidence and mortality, non-small cell lung cancer (NSCLC) is the most common type of lung cncer. For advanced lung cancer, traditional chemotherapy and targeted therapy become difficult to solve the dilemma of further progress. In recent years, with the clinical application of immunotherapy, the therapeutic strategy of lung cancer has changed dramatically. At present, immunotherapy has shown conspicuous efficacy in NSCLC patients with high expression of programmed death-ligand 1 (PD-L1) and high tumor mutational burden (TMB). The discovery of driver mutations brings delightful hope for targeted cancer therapy. However, it remains controversial whether immunotherapy can be used in NSCLC patients with these specific driver mutations. METHOD: This article summarized the latest research progresses of immunotherapy in advanced NSCLC. We paid close attention to the relevance of various driver mutations and immunotherapy in NSCLC patients, and summarized the predictive effects of several driver mutations and immunotherapy. RESULTS: The mutations of KRAS, KRAS+TP53, EPHA (especially EPHA5), ZFHX3, ZFHX3+TP53, NOTCH, BRAF and LRP1B+FAT3 have potential to be used as biomarkers to predict the positive effectiveness of immunotherapy. ZFHX3, ZFHX3+TP53, STKII/LKB1+KEAP1+SMARCA4+PBRM1 mutations in LUAD patients get more positive effect in immunotherapy. While the mutations of EGFR, KEAP1, STKII/LKB1+KRAS, EML4-ALK, MET exon 14 skipping mutation, PBRM1, STKII/LKB1+KEAP1+SMARCA4+PBRM1, ERBB2, PIK3CA and RET often indicate poor benefit from immunotherapy. CONCLUSION: Many gene mutations have been shown to be associated with immunotherapy efficacy. Gene mutations should be combined with PD-L1, TMB, etc. to predict the effect of immunotherapy. Springer Berlin Heidelberg 2023-06-01 2023 /pmc/articles/PMC10423141/ /pubmed/37261523 http://dx.doi.org/10.1007/s00432-023-04919-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Cai, Ruoxue Zhu, Hongyu Liu, Ying Sha, Huanhuan Peng, Weiwei Yin, Rong Zhou, Guoren Fang, Ying To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations |
title | To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations |
title_full | To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations |
title_fullStr | To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations |
title_full_unstemmed | To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations |
title_short | To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations |
title_sort | to be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423141/ https://www.ncbi.nlm.nih.gov/pubmed/37261523 http://dx.doi.org/10.1007/s00432-023-04919-4 |
work_keys_str_mv | AT cairuoxue tobeornottobethedilemmaofimmunotherapyfornonsmallcelllungcancerharboringvariousdrivermutations AT zhuhongyu tobeornottobethedilemmaofimmunotherapyfornonsmallcelllungcancerharboringvariousdrivermutations AT liuying tobeornottobethedilemmaofimmunotherapyfornonsmallcelllungcancerharboringvariousdrivermutations AT shahuanhuan tobeornottobethedilemmaofimmunotherapyfornonsmallcelllungcancerharboringvariousdrivermutations AT pengweiwei tobeornottobethedilemmaofimmunotherapyfornonsmallcelllungcancerharboringvariousdrivermutations AT yinrong tobeornottobethedilemmaofimmunotherapyfornonsmallcelllungcancerharboringvariousdrivermutations AT zhouguoren tobeornottobethedilemmaofimmunotherapyfornonsmallcelllungcancerharboringvariousdrivermutations AT fangying tobeornottobethedilemmaofimmunotherapyfornonsmallcelllungcancerharboringvariousdrivermutations |